Roche gets CE mark for blood test detecting Alzheimer's pathology, enabling faster, less invasive diagnosis worldwide.

Roche has received CE Mark approval for Elecsys® pTau217, a blood test that detects phosphorylated Tau 217 protein linked to Alzheimer's disease pathology. This test offers a minimally invasive, accurate alternative to current diagnostic methods like PET scans and spinal fluid analysis, which are costly and less accessible. It aims to speed up diagnosis, which currently takes an average of 3.5 years, and help identify Alzheimer's earlier, improving patient care and reducing healthcare system burdens. The test is set for broad implementation in CE-mark countries and may expand to the US pending FDA approval.